Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences gilead R&D expense recorded under Arcus Biosciences collaboration ($M) ($M)
Form 10-K Note 7 Collaborations and Other Arrangements
Latest, FY2025
218
Period ended Dec 31, 2025
Change on a year earlier
-10.3%
243 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gilead R&D expense recorded under Arcus Biosciences collaboration ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 218 | -10.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 243 | +28.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 189 | +1.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 187 | -70.1% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 625 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Gilead R&D expense recorded under Arcus Biosciences collaboration ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd_arcus_collab
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.